The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Artificial Intelligence Applied to clinical trials: opportunities and challenges
Open accessAbstract
Background Clinical Trials (CTs) remain the foundation of safe and effective drug development. Given the evolving data-driven and personalized medicine approach in healthcare, it is imperative for companies and regulators to utilize tailored Artificial Intelligence (AI) solutions that enable expeditious and streamlined clinical research. In this paper, we identified opportunities, challenges, and potential implications of AI in CTs. Methods Following an extensive search in relevant databases and websites, we gathered publications tackling the use of AI and Machine Learning (ML) in CTs from the past 5 years in the US and Europe, including Regulatory Authorities' documents. Results Documented applications of AI commonly concern the oncology field and are mostly being applied in the area of recruitment. Main opportunities discussed aim to create efficiencies across CT activities, including the ability to reduce sample sizes, improve enrollment and conduct faster, more optimized adaptive CTs. While AI is an area of enthusiastic development, the identified challenges are ethical in nature and relate to data availability, standards, and most importantly, lack of regulatory guidance hindering the acceptance of AI tools in drug development. However, future implications are significant and are anticipated to improve the probability of success, reduce trial burden and overall, speed up research and regulatory approval. Conclusion The use of AI in CTs is in its relative infancy; however, it is a fast-evolving field. As regulators provide more guidance on the acceptability of AI in specific areas, we anticipate the scope of use to broaden and the volume of implementation to increase rapidly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, AI is limited by the data it is trained on and an inability to account for the nuanced contexts of individual research studies [2].”
From Leveraging AI Large Language Models for Writing Clinical Trial Proposals in Dermatology: Instrument Validation Study (2026) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Artificial intelligence for clinical trial design
Harrer, S., Shah, P., Antony, B., & Hu, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.005 · Cited by 672
Artificial Intelligence for Drug Toxicity and Safety
Basile, A. O., Yahi, A., & Tatonetti, N. P. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.005 · Cited by 401
The role of machine learning in clinical research: transforming the future of evidence generation
Weissler, E. H., Naumann, T., Andersson, T., Ranganath, R., Elemento, O., Luo, Y., Freitag, D. F., Benoit, J. R. A., Hughes, M. C., Khan, F. M., et al. (2021) · Trials · doi:10.1186/s13063-021-05489-x · Cited by 320
Artificial intelligence in drug design
Zhong, F., Xing, J., Li, X., Liu, X., Fu, Z., Xiong, Z., Lu, D., Wu, X., Zhao, J., Tan, X., et al. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9342-2 · Cited by 293
Will Artificial Intelligence for Drug Discovery Impact Clinical Pharmacology?
Zhavoronkov, A., Vanhaelen, Q., & Oprea, T. I. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1795 · Cited by 159
Beck, J. T., Rammage, M., Jackson, G. P., Preininger, A. M., Dankwa-Mullan, I., Roebuck, M. C., Torres, A., Holtzen, H., Coverdill, S. E., Williamson, M. P., et al. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00079 · Cited by 127
EliIE: An open-source information extraction system for clinical trial eligibility criteria
Kang, T., Zhang, S., Tang, Y., Hruby, G. W., Rusanov, A., Elhadad, N., & Weng, C. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocx019 · Cited by 110
Calaprice, D., Galil, K., Salloum, W., Zariv, A., & Jimenez, B. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-019-00030-4 · Cited by 89
Haddad, T. C., Helgeson, J. M., Pomerleau, K., Preininger, A. M., Roebuck, M. C., Dankwa‐Mullan, I., Jackson, G. P., & Goetz, M. P. (2021) · JMIR Medical Informatics · doi:10.2196/27767 · Cited by 79
The Missing Pieces of Artificial Intelligence in Medicine
Gilvary, C. M., Madhukar, N. S., Elkhader, J. A., & Elemento, O. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.06.001 · Cited by 78
Machine learning for clinical trials in the era of COVID-19
Zame, W. R., Bica, I., Shen, C., Curth, A., Lee, H.-S., Bailey, S., Weatherall, J. H., Wright, D. N. M., Bretz, F., & van der Schaar, M. (2020) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2020.1797867 · Cited by 70
How Artificial Intelligence Can Transform Randomized Controlled Trials
Lee, C. S., & Lee, A. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.2.9 · Cited by 68
Key indicators of phase transition for clinical trials through machine learning
Feijoo, F., Palopoli, M., Bernstein, J., Siddiqui, S., & Albright, T. E. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.014 · Cited by 65
Accuracy of machine learning-based prediction of medication adherence in clinical research
Koesmahargyo, V., Abbas, A., Zhang, L., Guan, L., Feng, S., Yadav, V., & Galatzer‐Levy, I. R. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113558 · Cited by 62
Zhang, K., & Demner‐Fushman, D. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw176 · Cited by 55
Clinical trial cohort selection based on multi-level rule-based natural language processing system
Chen, L., 池谷, 裕., Ji, X., Lou, C., Sun, Z., Li, H., Gao, Y., & Huang, Y. H. (2019) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocz109 · Cited by 48
The case for AI-driven cancer clinical trials – The efficacy arm in silico
Kolla, L., Gruber, F. K., Khalid, O. M., Hill, C., & Parikh, R. B. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188572 · Cited by 46
A knowledge base of clinical trial eligibility criteria
Liu, H., Yuan, C., Butler, A. M., Sun, Y., & Weng, C. (2021) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2021.103771 · Cited by 42
Siah, K. W., Khozin, S., Wong, C. H., & Lo, A. W. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00046 · Cited by 38
Krittanawong, C., Johnson, K. W., & Tang, W. H. W. (2019) · Personalized Medicine · doi:10.2217/pme-2018-0130 · Cited by 37
How to Design AI-Driven Clinical Trials in Nuclear Medicine
Delso, G., Cirillo, D., Kaggie, J. D., Valencia, A., Metser, U., & Veit-Haibach, P. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.09.003 · Cited by 36 · cited 5×
“Understanding the factors influencing success and failure per phase (mainly complexity of the protocol, selection of clinical endpoints, of the interventional arm and of the eligibility criteria) impacts the trial design in current and subsequent phases [3, 12].”
BackgroundMethodInfluentialAnsart, M., Epelbaum, S., Gagliardi, G. P., Olivier Colliot, A., Dormont, D., Dubois, B., Hampel, H. J., Durrleman, S., & Initiative, A. D. N. (2019) · Statistical Methods in Medical Research · doi:10.1177/0962280218823036 · Cited by 36
Optimizing clinical trials recruitment via deep learning
Gligorijević, J., Gligorijevic, D., Pavlovski, M., Milkovits, E., Glass, L. M., Grier, K., Vankireddy, P., & Zoran Obradovic, A. (2019) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocz064 · Cited by 31
Quantifying representativeness in randomized clinical trials using machine learning fairness metrics
Qi, M., Cahan, O., Foreman, M. A., Gruen, D. M., Das, A. K., & Bennett, K. P. (2021) · JAMIA Open · doi:10.1093/jamiaopen/ooab077 · Cited by 27
Gates, A., Gates, M., Sim, S., Elliott, S. A., Pillay, J., & Hartling, L. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01354-2 · Cited by 25
Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials
Schperberg, A. V., Boichard, A., Tsigelny, I. F., Richard, S. B., & Kurzrock, R. (2020) · International Journal of Cancer · doi:10.1002/ijc.33240 · Cited by 24
The Role of AI in Clinical Trials
Mayorga-Ruiz, I., Jiménez-Pastor, A., Fos-Guarinos, B., López‐González, R., García-Castro, F., & Alberich‐Bayarri, Á. (2019) · Springer eBooks · doi:10.1007/978-3-319-94878-2_16 · Cited by 23
Hybrid bag of approaches to characterize selection criteria for cohort identification
Vydiswaran, V. G. V., Strayhorn, A., Zhao, X., Robinson, P., Agarwal, M., Bagazinski, E., Essiet, M., Iott, B. E., Joo, H., Ko, P., et al. (2019) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocz079 · Cited by 22
Vazquez, J., Abdelrahman, S., Byrne, L. M., Russell, M., Harris, P. A., & Facelli, J. C. (2020) · Journal of Clinical and Translational Science · doi:10.1017/cts.2020.535 · Cited by 19
Sangari, N., & Qu, Y. (2020) · International Conference on Computational Science and Computational Intelligence (CSCI) · doi:10.1109/csci51800.2020.00152 · Cited by 18
Zhou, N., & Manser, P. T. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51140 · Cited by 13
Beaulieu, D., Berry, J. D., Paganoni, S., Glass, J. D., Fournier, C. N., Cuerdo, J., Schactman, M., & Ennist, D. L. (2021) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2021.1924207 · Cited by 12
Goldstein, B. A., & Rigdon, J. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.0004 · Cited by 11
Automatic data source identification for clinical trial eligibility criteria resolution.
Shivade, C., Hebert, C. L., Regan, K., Fosler‐Lussier, E., & Lai, A. M. (2016) · PubMed Central · Cited by 8
Assessing the Scope and Predictors of Intentional Dose Non-adherence in Clinical Trials
Getz, K. A., Smith, Z., Shafner, L., & Hanina, A. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00155-x · Cited by 7
Research works printed but not linked: 2
- Weissler EH, Naumann T, Andersson T, et al. The role of machine learning in clinical research: transforming the future of evidence generation. Trials. 2021;22(1). https://doi.org/10.1186/s13063-021-05489-x. · DOI
- European Commission’s Heads of Medicines Agency. Joint HMA/EMA workshop on artificial intelligence in medicines regulation | European Medicines Agency. Published 2021. Accessed October 17., 2021. https://www.ema.europa.eu/en/events/joint-hmaema-workshop-artificial-intelligence-medicines-regulation
Cited by
Sorted by citations
Current AI technologies in cancer diagnostics and treatment
Tiwari, A., Mishra, S. N., & Kuo, T. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02369-9 · Cited by 257
Advances in artificial intelligence for drug delivery and development: A comprehensive review
Gholap, A. D., Uddin, M. J., Faiyazuddin, M., Omri, A., Gowri, S., & Khalid, M. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108702 · Cited by 197
Revolutionizing clinical trials: the role of AI in accelerating medical breakthroughs
Chopra, H., Annu, A., Shin, D. K., Munjal, K., Priyanka, Dhama, K., & Emran, T. B. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000705 · Cited by 189
Tribulations and future opportunities for artificial intelligence in precision medicine
Carini, C., & Seyhan, A. A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05067-0 · Cited by 221
Dzau, V. J., & Hodgkinson, C. P. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21710 · Cited by 155
Metadata
- Authors
- Askin, S., Burkhalter, D., Calado, G., & El Dakrouni, S.
- Affiliations
- Novartis (Switzerland) (CH)
- Massachusetts College of Pharmacy and Health Sciences (US)
- Corresponding author
- Askin, Scott
- Venue
- Health and Technology
- Published
- 2023-02-28
- Volume
- 13
- Issue
- 2
- Pages
- 203-213
- ISSN
- 2190-7188 (ISSN-L)
- 2190-7196
- PMC
- PMC9974218
- OpenAlex
- W4322621757
- Cited by
- 285
- References
- 36
- Citations by year
- 2026: 61 · 2025: 123 · 2024: 83 · 2023: 18
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Health and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Physical Sciences › Computer Science › Artificial Intelligence › Artificial Intelligence Applications
- Keywords
- artificial intelligence in clinical trials, machine learning, adaptive clinical trials, clinical trial recruitment, cancer clinical trials, ethical challenges of AI, data availability, drug development, personalized medicine, trial efficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
